Log in to your Inderes Free account to see all free content on this page.

Intervacc

0.90 SEK

+2.16 %

Less than 1K followers

IVACC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+2.16 %

-6.83 %

-23.60 %

-16.51 %

-10.34 %

-59.65 %

-95.82 %

-97.41 %

-83.73 %

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Market cap

306.73M SEK

Turnover

105.64K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

17.2.

2026

Annual report '25

All

Press releases

3rd party

ShowingAll content types

Press release11/20/2025, 6:52 AM

DNB Carnegie Access: Intervacc: Solid quarter with strong sales growth – Q3 review

Press release11/19/2025, 12:16 PM

DNB Carnegie Access: Intervacc – Försäljningen i Q3 tar ett skutt uppåt

Regulatory press release11/19/2025, 7:30 AM

Intervacc: Interim report January - September 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release10/13/2025, 6:20 AM

Intervacc and Dechra extend distribution agreement for Intervacc's equine strangles vaccine Strangvac by two years

Regulatory press release9/25/2025, 6:30 AM

Intervacc appoints Anna-Carin Lagerlöf as Sales and Marketing Director

Press release9/1/2025, 5:55 AM

DNB Carnegie Access: Intervacc: Strangvac gains traction – Q2 review

Regulatory press release8/29/2025, 6:30 AM

Intervacc: Interim report January - June 2025

Press release8/20/2025, 1:22 PM

DNB Carnegie Access: Intervacc: Sales gaining momentum – Q2 preview

Regulatory press release8/18/2025, 11:00 AM

Intervacc's distribution partner Dechra launches Strangvac in Spain, Portugal and Slovenia

Regulatory press release5/14/2025, 2:15 PM

Report from Annual General Meeting in Intervacc

Regulatory press release5/14/2025, 6:30 AM

Intervacc: Interim report January - March 2025

Regulatory press release5/5/2025, 11:15 AM

Intervacc's distribution partner Dechra launches Strangvac in Finland

Press release4/16/2025, 7:45 AM

Article on Intervacc's Streptococcus suis study published in the journal Vaccine

Regulatory press release4/11/2025, 1:30 PM

Notice of Annual General Meeting in Intervacc AB (publ)

Regulatory press release4/4/2025, 6:30 AM

Intervacc publishes the 2024 Annual Report

Regulatory press release3/28/2025, 2:15 PM

Intervacc's variation application approved by VMD

Regulatory press release3/17/2025, 4:40 PM

Intervacc announces changes in the Nomination Committee

Regulatory press release2/24/2025, 6:55 PM

Intervacc announces the outcome of the rights issue

Regulatory press release2/13/2025, 5:45 PM

Intervacc's variation application approved by European Medicines Agency

Regulatory press release2/13/2025, 2:00 PM

Intervacc AB (publ) publishes supplement to the prospectus regarding the rights issue

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.